The vesicles promote metastasis after chemotherapy, but the authors say the results shouldn’t alarm patients and may point to ways to improve treatments.
Checkpoint inhibition combined with chemotherapy gives patients with triple-negative metastatic breast cancer about two months more time without significant tumor growth, a study finds.
Mice with cancer whose KRAS proteins couldn’t link together had much better survival outcomes than those whose oncogenic mutant paired with wild-type KRAS.